https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01645-6
chatGPT:
Here’s a structured review of the uploaded paper, Hypoxia-inducible factor 1 protects neurons from Sarm1-mediated neurodegeneration.
Summary
The paper asks how Sarm1, a central executioner of axon degeneration through its NAD+ hydrolase activity, is regulated. Using genome-wide CRISPR-Cas9 survival screens in human cell lines expressing constitutively active SARM1, the authors identify VHL and other Cullin-2 RING ligase (CRL2) components/substrate receptors as suppressors of Sarm1-driven degeneration. They then connect this to HIF-1, because VHL normally targets HIF-1α for oxygen-dependent degradation.
They show in primary mouse DRG and cortical neurons that genetic disruption of Vhl/CRL2-related machinery, or expression of a stabilized non-degradable Hif1a-S construct, protects against axotomy-induced degeneration. This protection also extends to Vacor, a direct pharmacologic Sarm1 activator, and to an inducible dimerized Sarm1 TIR-domain construct, implying the effect is not limited to one activation route upstream of Sarm1.
A key mechanistic result is that stabilized HIF-1 reduces or delays the loss of NAD+ after Sarm1 activation. The authors also show that HIF-1-mediated protection requires DNA binding and days of prior expression, supporting a transcription-dependent mechanism rather than an acute direct biochemical block. RNA-seq confirms that HIF-1 profoundly rewires neuronal transcription, although the exact downstream protective effector(s) remain unresolved.
They further show in vivo protection in Drosophila, where stabilized mouse Hif1a-S protects fly sensory neurons after axotomy and in a dNmnat knockdown model. Overall, the paper argues that hypoxia/HIF-1 signaling antagonizes Sarm1-mediated neurodegeneration, providing a plausible molecular explanation for some neuroprotective effects of hypoxia.
What is novel
The main novelty is the identification of a hypoxia–HIF-1–Sarm1 axis. Hypoxia had already been associated with neuroprotection, and Sarm1 was already known as a core axon-death factor, but this study links them mechanistically by showing that stabilized HIF-1 suppresses Sarm1-dependent degeneration. The authors themselves frame this as an unexpected discovery.
A second novel point is the claim that HIF-1 can suppress degeneration even when Sarm1 is engaged very directly, including Vacor-triggered activation and even TIR-domain-driven NAD+ hydrolase output. That is more surprising than merely showing protection upstream of Sarm1, because it suggests HIF-1-induced cellular changes can oppose the degenerative program close to, or at the level of, Sarm1 enzymatic action in cells.
A third novel aspect is the implication that multiple CRL2 substrate receptors/adaptors, not just canonical VHL, may participate in keeping neuronal HIF-1 suppressed in normoxia. That is interesting conceptually, although still provisional mechanistically.
A fourth strength is the cross-system consistency: human cell-line screens, mouse primary neurons, and fly in vivo models all point in the same direction. That makes the overall biological claim more persuasive than a single-system paper.
Critique
The biggest limitation is that the paper does not identify the downstream mechanism by which HIF-1 suppresses Sarm1-mediated NAD+ loss and degeneration. The RNA-seq shows many transcriptional changes, but the causal effector genes are not pinned down. The authors acknowledge this directly.
Related to that, the paper sometimes comes close to implying that HIF-1 functionally inhibits Sarm1 “itself,” but the data do not yet prove a direct inhibitor of Sarm1 exists. The authors explicitly present alternative models: increased NAD+ support, reduced consumption elsewhere, or an induced factor that blocks Sarm1 signaling directly or indirectly. At present, the mechanism remains an informed hypothesis, not a resolved pathway.
The CRISPR screen-to-neuron validation gap is also important. The paper notes that only a handful of screening hits validated in primary neurons, and overlap between HeLa and HEK293T screens was limited. That weakens confidence that the screen comprehensively captured physiologically relevant Sarm1 regulators.
The in vivo evidence, while useful, is not yet definitive for mammalian neurobiology. The fly experiments use heterologous mouse Hif1a-S, which is clever but indirect. The authors acknowledge that endogenous fly HIF components were not directly manipulated, and that the effect of stabilized HIF-1 remains untested in vivo in mice. That leaves an important translational gap.
There is also a possible concern about pleiotropy. HIF-1 is a master transcription factor that alters hundreds of genes, including glycolytic and classic hypoxia-response genes, some not obviously neuron-specific. That broad state change may indeed be protective, but it makes it harder to separate a specific anti-Sarm1 pathway from a more general metabolic stress program.
Finally, the therapeutic framing should be treated cautiously. The paper makes a plausible case that hypoxia/HIF-1 signaling could be exploited against Sarm1-mediated neurodegeneration, but HIF-1 activation has many systemic effects, and the study does not establish a safe or selective translational route. The therapeutic implication is promising, but still early.
Bottom line
This is a strong and interesting paper. Its main contribution is to show that stabilized HIF-1 protects neurons from Sarm1-dependent degeneration and reduces Sarm1-associated NAD+ loss, providing a molecular bridge between hypoxia biology and axon degeneration biology. The work is broad, technically solid, and conceptually important. Its main weakness is that the protective mechanism downstream of HIF-1 is still unresolved, so the paper is more of a major pathway discovery than a complete mechanistic dissection.
I can also turn this into a claim-by-claim table with columns for claim, evidence, novelty, and weakness.